John M. Burke

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

Toni K. Choueiri, Piotr Tomczak, Se Hoon Park et al. · New England Journal of Medicine · 2021 · 708 citations · Full text

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

Ian W. Flinn, Richard van der Jagt, Brad S. Kahl et al. · Blood · 2014 · 623 citations · Full text

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma

Umberto Vitolo, Marek Trněný, David Belada et al. · Journal of Clinical Oncology · 2017 · 414 citations

Advanced-stage Dlbcl, Lymphoid Neoplasia, Hematological Malignancy +13

First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study

Ian W. Flinn, Richard van der Jagt, Brad S. Kahl et al. · Journal of Clinical Oncology · 2019 · 286 citations · Full text

Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma

Robert J. Motzer, Thomas E. Hutson, Mark R. Olsen et al. · Journal of Clinical Oncology · 2012 · 275 citations · Full text